Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
New to MyHealth?
Manage Your Care From Anywhere.
Access your health information from any device with MyHealth. ÌýYou can message your clinic, view lab results, schedule an appointment, and pay your bill.
ALREADY HAVE AN ACCESS CODE?
DON'T HAVE AN ACCESS CODE?
NEED MORE DETAILS?
MyHealth for Mobile
WELCOME BACK
or
A Phase Ib/IIa randomized pilot study to investigate the safety and tolerability of autologous T-cells with enhanced T-cell receptors specific to NY-ESO-1/LAGE-1a (GSK3377794) alone, or in combination with pembrolizumab, in advanced non-small cell lung cancer
ÌÇÐÄ´«Ã½
A Phase Ib/IIa randomized pilot study to investigate the safety and tolerability of autologous T-cells with enhanced T-cell receptors specific to NY-ESO-1/LAGE-1a (GSK3377794) alone, or in combination with pembrolizumab, in advanced non-small cell lung cancer Reckamp, K. L., Akerley, W., Edelman, M. J., Halmos, B., He, K., Johnson, M., Mudad, R., Neal, J. W., Owonikoko, T. K., Patel, J. D., Patel, S. P., Riess, J. W., Sacher, A. G., Turcotte, S., Villaruz, L. C., Zauderer, M. G., Farsaci, B., Hasan, A., Patel, R., Wu, Y., Chisamore, M., Lam, V. AMER ASSOC CANCER RESEARCH. 2019View details for
View details for